{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:00:04Z","timestamp":1793912404454,"version":"4.8.0"},"reference-count":165,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Natural Science Foundation of Southwest Medical University","award":["2022QN079"],"award-info":[{"award-number":["2022QN079"]}]},{"name":"Natural Science Foundation of Southwest Medical University","award":["00180156"],"award-info":[{"award-number":["00180156"]}]},{"name":"Natural Science Foundation of Southwest Medical University","award":["202210632091"],"award-info":[{"award-number":["202210632091"]}]},{"name":"Natural Science Foundation of Southwest Medical University","award":["S202210632244"],"award-info":[{"award-number":["S202210632244"]}]},{"name":"Talent Recruitment Program of Southwest Medical University","award":["2022QN079"],"award-info":[{"award-number":["2022QN079"]}]},{"name":"Talent Recruitment Program of Southwest Medical University","award":["00180156"],"award-info":[{"award-number":["00180156"]}]},{"name":"Talent Recruitment Program of Southwest Medical University","award":["202210632091"],"award-info":[{"award-number":["202210632091"]}]},{"name":"Talent Recruitment Program of Southwest Medical University","award":["S202210632244"],"award-info":[{"award-number":["S202210632244"]}]},{"name":"College Student Innovation and Entrepreneurship Training Program","award":["2022QN079"],"award-info":[{"award-number":["2022QN079"]}]},{"name":"College Student Innovation and Entrepreneurship Training Program","award":["00180156"],"award-info":[{"award-number":["00180156"]}]},{"name":"College Student Innovation and Entrepreneurship Training Program","award":["202210632091"],"award-info":[{"award-number":["202210632091"]}]},{"name":"College Student Innovation and Entrepreneurship Training Program","award":["S202210632244"],"award-info":[{"award-number":["S202210632244"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The three-year COVID-19 pandemic \u2018has\u2019 caused a wide range of medical, social, political, and financial implications. Since the end of 2020, various mutations and variations in SARS-CoV-2 strains, along with the immune escape phenomenon, have emerged. There is an urgent need to identify a relatively stable target for the development of universal vaccines and drugs that can effectively combat both SARS-CoV-2 strains and their mutants. Currently, the main focus in treating SARS-CoV-2 lies in disrupting the virus\u2019s life cycle. The main protease (Mpro) is closely associated with virus replication and maturation and plays a crucial role in the early stages of infection. Consequently, it has become an important target for the development of SARS-CoV-2-specific drugs. This review summarizes the recent research progress on the novel coronavirus\u2019s main proteases, including the pivotal role of Mpro in the virus\u2019s life cycle, the structure and catalytic mechanism of Mpro, the self-maturation mechanism of Mpro, the role of Mpro in virus immune escape, the current methods of developing antiviral drugs targeting Mpro, and the key drugs that have successfully entered clinical trials. The aim is to provide researchers involved in the development of antiviral drugs targeting Mpro with systematic and comprehensive information.<\/jats:p>","DOI":"10.3390\/molecules30020351","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T09:58:36Z","timestamp":1737021516000},"page":"351","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Research Progress on the Structure and Function, Immune Escape Mechanism, Antiviral Drug Development Methods, and Clinical Use of SARS-CoV-2 Mpro"],"prefix":"10.3390","volume":"30","author":[{"given":"Jiayi","family":"Ren","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengfu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingqin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8916-9368","authenticated-orcid":false,"given":"Shujun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e105938","DOI":"10.15252\/embj.2020105938","article-title":"Structures of the SARS-CoV-2 nucleocapsid and their perspectives for drug design","volume":"39","author":"Peng","year":"2020","journal-title":"EMBO J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"100682","DOI":"10.1016\/j.genrep.2020.100682","article-title":"Genomic characterization of a novel SARS-CoV-2","volume":"19","author":"Khailany","year":"2020","journal-title":"Gene Rep."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Choudhary, S., Malik, Y.S., and Tomar, S. (2020). Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using in silico Structure-Based Virtual Screening Approach. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01664"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00044-022-02951-6","article-title":"The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): An orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations","volume":"31","author":"Joyce","year":"2022","journal-title":"Med. Chem. Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"M\u00f3ty\u00e1n, J.A., Mahdi, M., Hoffka, G., and T\u0151zs\u00e9r, J. (2022). Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073507"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"8686","DOI":"10.1021\/acs.jmedchem.2c00404","article-title":"Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Mandal, A., Jha, A.K., and Hazra, B. (2021). Plant Products as Inhibitors of Coronavirus 3CL Protease. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.583387"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s12250-021-00431-6","article-title":"Structure and Function of N-Terminal Zinc Finger Domain of SARS-CoV-2 NSP2","volume":"36","author":"Ma","year":"2021","journal-title":"Virol. Sin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"10543","DOI":"10.1021\/jacs.2c03320","article-title":"Atomic-Resolution Structure of SARS-CoV-2 Nucleocapsid Protein N-Terminal Domain","volume":"144","author":"Sarkar","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Szekely, J., Mongkolprasert, J., Jeayodae, N., Senorit, C., Chaimuti, P., Swangphon, P., Nanakorn, N., Nualnoi, T., Wongwitwichot, P., and Pengsakul, T. (2022). Development, Analytical, and Clinical Evaluation of Rapid Immunochromatographic Antigen Test for SARS-CoV-2 Variants Detection. Diagnostics, 12.","DOI":"10.3390\/diagnostics12020381"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Huang, Y., Chen, J., Chen, S., Huang, C., Li, B., Li, J., Jin, Z., Zhang, Q., Pan, P., and Du, W. (2024). Molecular characterization of SARS-CoV-2 nucleocapsid protein. Front. Cell. Infect. Microbiol., 14.","DOI":"10.3389\/fcimb.2024.1415885"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12985-023-01968-6","article-title":"The SARS-CoV-2 nucleocapsid protein: Its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics","volume":"20","author":"Wu","year":"2023","journal-title":"Virol. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: Implications for SARS-CoV-2","volume":"19","author":"Kratzel","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41392-021-00653-w","article-title":"Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Singh, E., Khan, R.J., Jha, R.K., Amera, G.M., Jain, M., Singh, R.P., Muthukumaran, J., and Singh, A.K. (2020). A comprehensive review on promising anti-viral therapeutic candidates identified against main protease from SARS-CoV-2 through various computational methods. J. Genet. Eng. Biotechnol., 18.","DOI":"10.1186\/s43141-020-00085-z"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1152\/physiolgenomics.00087.2020","article-title":"SARS-CoV-2, ACE2 expression, and systemic organ invasion","volume":"53","author":"Ashraf","year":"2021","journal-title":"Physiol. Genom."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wang, J., Zhao, H., and An, Y. (2021). ACE2 Shedding and the Role in COVID-19. Front. Cell. Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.789180"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zipeto, D., Palmeira, J.D.F., Arga\u00f1araz, G.A., and Arga\u00f1araz, E.R. (2020). ACE2\/ADAM17\/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.576745"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101973","DOI":"10.1016\/j.mcp.2024.101973","article-title":"SARS-CoV-2 replication and drug discovery","volume":"77","author":"Nazir","year":"2024","journal-title":"Mol. Cell. Probes"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Deng, M., Zhang, C., Yan, W., Chen, L., He, B., and Li, Y. (2024). Development of Fluorescence-Based Assays for Key Viral Proteins in the SARS-CoV-2 Infection Process and Lifecycle. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052850"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"34196","DOI":"10.1021\/acsomega.4c03023","article-title":"Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (M(pro))","volume":"9","author":"Yang","year":"2024","journal-title":"ACS Omega"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Al Adem, K., Ferreira, J.C., Villanueva, A.J., Fadl, S., El-Sadaany, F., Masmoudi, I., Gidiya, Y., Gurudza, T., Cardoso, T.H.S., and Saksena, N.K. (2024). 3-chymotrypsin-like protease in SARS-CoV-2. Biosci. Rep., 44.","DOI":"10.1042\/BSR20231395"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41564-021-00958-0","article-title":"Cellular host factors for SARS-CoV-2 infection","volume":"6","author":"Baggen","year":"2021","journal-title":"Nat. Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1128\/JVI.01358-06","article-title":"A contemporary view of coronavirus transcription","volume":"81","author":"Sawicki","year":"2007","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"113584","DOI":"10.1016\/j.ejmech.2021.113584","article-title":"Improved SARS-CoV-2 M(pro) inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies","volume":"222","author":"Vuong","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Outteridge, M., Nunn, C.M., Devine, K., Patel, B., and McLean, G.R. (2024). Antivirals for Broader Coverage against Human Coronaviruses. Viruses, 16.","DOI":"10.3390\/v16010156"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","article-title":"An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy","volume":"59","author":"Pillaiyar","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1038\/s41467-020-18096-2","article-title":"Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication","volume":"11","author":"Vuong","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nrd3053","article-title":"Emerging principles in protease-based drug discovery","volume":"9","author":"Drag","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"16922","DOI":"10.1021\/acs.jmedchem.1c00409","article-title":"Perspectives on SARS-CoV-2 Main Protease Inhibitors","volume":"64","author":"Gao","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ejmech.2013.07.037","article-title":"Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: Design, synthesis, biological evaluation, and docking studies","volume":"68","author":"Thanigaimalai","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1039\/D1MD00066G","article-title":"A review of the latest research on M(pro) targeting SARS-COV inhibitors","volume":"12","author":"Yang","year":"2021","journal-title":"RSC Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coviro.2021.09.005","article-title":"Virus structure and structure-based antivirals","volume":"51","author":"Plavec","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1128\/JVI.02612-07","article-title":"Without its N-finger, the main protease of severe acute respiratory syndrome coronavirus can form a novel dimer through its C-terminal domain","volume":"82","author":"Zhong","year":"2008","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Citarella, A., Scala, A., Piperno, A., and Micale, N. (2021). SARS-CoV-2 M(pro): A Potential Target for Peptidomimetics and Small-Molecule Inhibitors. Biomolecules, 11.","DOI":"10.3390\/biom11040607"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Citarella, A., Dimasi, A., Moi, D., Passarella, D., Scala, A., Piperno, A., and Micale, N. (2023). Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives. Biomolecules, 13.","DOI":"10.20944\/preprints202308.0055.v1"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1002\/mco2.151","article-title":"The SARS-CoV-2 main protease (M(pro)): Structure, function, and emerging therapies for COVID-19","volume":"3","author":"Hu","year":"2022","journal-title":"MedComm"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"13190","DOI":"10.1073\/pnas.1835675100","article-title":"The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor","volume":"100","author":"Yang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Macip, G., Garcia-Segura, P., Mestres-Truyol, J., Saldivar-Espinoza, B., Pujadas, G., and Garcia-Vallv\u00e9, S. (2021). A Review of the Current Landscape of SARS-CoV-2 Main Protease Inhibitors: Have We Hit the Bullseye Yet?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010259"},{"key":"ref_44","first-page":"99","article-title":"Potential SARS-COV preclinical (in vivo) compounds targeting COVID-19 main protease: A meta-analysis and molecular docking studies","volume":"24","author":"Ebenezer","year":"2020","journal-title":"Hippokratia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/emboj\/cdf327","article-title":"Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain","volume":"21","author":"Anand","year":"2002","journal-title":"EMBO J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.virol.2009.03.034","article-title":"Two adjacent mutations on the dimer interface of SARS coronavirus 3C-like protease cause different conformational changes in crystal structure","volume":"388","author":"Hu","year":"2009","journal-title":"Virology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/jmv.25766","article-title":"Coronavirus disease 2019: What we know?","volume":"92","author":"He","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Mengist, H.M., Dilnessa, T., and Jin, T. (2021). Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease. Front. Chem., 9.","DOI":"10.3389\/fchem.2021.622898"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Cui, W., Yang, K., and Yang, H. (2020). Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19. Front. Mol. Biosci., 7.","DOI":"10.3389\/fmolb.2020.616341"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1128\/JVI.02114-07","article-title":"Structures of two coronavirus main proteases: Implications for substrate binding and antiviral drug design","volume":"82","author":"Xue","year":"2008","journal-title":"J. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bbrc.2020.10.091","article-title":"The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2","volume":"538","author":"Jin","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1021\/bi036022q","article-title":"3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism","volume":"43","author":"Huang","year":"2004","journal-title":"Biochemistry"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"31257","DOI":"10.1074\/jbc.M502577200","article-title":"Mechanism of the maturation process of SARS-CoV 3CL protease","volume":"280","author":"Hsu","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"28134","DOI":"10.1074\/jbc.M109.095851","article-title":"Maturation mechanism of severe acute respiratory syndrome (SARS) coronavirus 3C-like proteinase","volume":"285","author":"Li","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/rheumatology\/kep328","article-title":"Identification of anti-prothrombin antibodies in the anti-phospholipid syndrome that display the prothrombinase activity","volume":"49","author":"Yang","year":"2010","journal-title":"Rheumatology"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Noske, G.D., Nakamura, A.M., Gawriljuk, V.O., Fernandes, R.S., Lima, G.M.A., Rosa, H.V.D., Pereira, H.D., Zeri, A.C.M., Nascimento, A.F.Z., and Freire, M. (2021). A Crystallographic Snapshot of SARS-CoV-2 Main Protease Maturation Process. J. Mol. Biol., 433.","DOI":"10.1016\/j.jmb.2021.167118"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41590-020-00840-x","article-title":"Untuned antiviral immunity in COVID-19 revealed by temporal type I\/III interferon patterns and flu comparison","volume":"22","author":"Galani","year":"2021","journal-title":"Nat. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Song, L., Wang, D., Abbas, G., Li, M., Cui, M., Wang, J., Lin, Z., and Zhang, X.E. (2023). The main protease of SARS-CoV-2 cleaves histone deacetylases and DCP1A, attenuating the immune defense of the interferon-stimulated genes. J. Biol. Chem., 299.","DOI":"10.1016\/j.jbc.2023.102990"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/s41591-020-1021-2","article-title":"Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection","volume":"26","author":"Ramlall","year":"2020","journal-title":"Nat. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/biof.6","article-title":"Interferons and viral infections","volume":"35","author":"Fensterl","year":"2009","journal-title":"BioFactors"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1073\/pnas.1114981109","article-title":"Systematic identification of type I and type II interferon-induced antiviral factors","volume":"109","author":"Liu","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Kroetz, D.N., Allen, R.M., Schaller, M.A., Cavallaro, C., Ito, T., and Kunkel, S.L. (2015). Type I Interferon Induced Epigenetic Regulation of Macrophages Suppresses Innate and Adaptive Immunity in Acute Respiratory Viral Infection. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005338"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/1042819031000149368","article-title":"Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation","volume":"45","author":"Tough","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e23931","DOI":"10.4161\/jkst.23931","article-title":"Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway","volume":"2","author":"Mandhana","year":"2013","journal-title":"Jak-Stat"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19","volume":"181","author":"Liu","year":"2020","journal-title":"Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.chom.2020.04.009","article-title":"Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure","volume":"27","author":"Netea","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","article-title":"Longitudinal analyses reveal immunological misfiring in severe COVID-19","volume":"584","author":"Lucas","year":"2020","journal-title":"Nature"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.virol.2016.12.005","article-title":"Porcine deltacoronavirus nsp5 inhibits interferon-\u03b2 production through the cleavage of NEMO","volume":"502","author":"Zhu","year":"2017","journal-title":"Virology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.7150\/ijbs.59943","article-title":"SARS-CoV-2 main protease suppresses type I interferon production by preventing nuclear translocation of phosphorylated IRF3","volume":"17","author":"Fung","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1016\/j.molcel.2021.04.008","article-title":"Functional landscape of SARS-CoV-2 cellular restriction","volume":"81","author":"Lewinski","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"13033","DOI":"10.1074\/jbc.M212972200","article-title":"A hybrid IRF9-STAT2 protein recapitulates interferon-stimulated gene expression and antiviral response","volume":"278","author":"Kraus","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/385540a0","article-title":"MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1","volume":"385","author":"Malinin","year":"1997","journal-title":"Nature"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Qian, S., Fan, W., Liu, T., Wu, M., Zhang, H., Cui, X., Zhou, Y., Hu, J., Wei, S., and Chen, H. (2017). Seneca Valley Virus Suppresses Host Type I Interferon Production by Targeting Adaptor Proteins MAVS, TRIF, and TANK for Cleavage. J. Virol., 91.","DOI":"10.1128\/JVI.00823-17"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Chen, J., Wang, D., Sun, Z., Gao, L., Zhu, X., Guo, J., Xu, S., Fang, L., Li, K., and Xiao, S. (2019). Arterivirus nsp4 Antagonizes Interferon Beta Production by Proteolytically Cleaving NEMO at Multiple Sites. J. Virol., 93.","DOI":"10.1128\/JVI.00385-19"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1128\/JVI.02514-15","article-title":"Porcine Epidemic Diarrhea Virus 3C-Like Protease Regulates Its Interferon Antagonism by Cleaving NEMO","volume":"90","author":"Wang","year":"2016","journal-title":"J. Virol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Zhu, X., Chen, J., Tian, L., Zhou, Y., Xu, S., Long, S., Wang, D., Fang, L., and Xiao, S. (2020). Porcine Deltacoronavirus nsp5 Cleaves DCP1A To Decrease Its Antiviral Activity. J. Virol., 94.","DOI":"10.1128\/JVI.02162-19"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1074\/jbc.M113.518191","article-title":"mRNA decapping enzyme 1a (Dcp1a)-induced translational arrest through protein kinase R (PKR) activation requires the N-terminal enabled vasodilator-stimulated protein homology 1 (EVH1) domain","volume":"289","author":"Dougherty","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.4049\/jimmunol.1701773","article-title":"Porcine Reproductive and Respiratory Syndrome Virus Nonstructural Protein 4 Cleaves Porcine DCP1a To Attenuate Its Antiviral Activity","volume":"201","author":"Tao","year":"2018","journal-title":"J. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Liu, Y., Qin, C., Rao, Y., Ngo, C., Feng, J.J., Zhao, J., Zhang, S., Wang, T.Y., Carriere, J., and Savas, A.C. (2021). SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS To Evade the Innate Immune Response. mBio, 12.","DOI":"10.1128\/mBio.02335-21"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Zhou, K., and Chen, D. (2023). Conventional Understanding of SARS-CoV-2 M(pro) and Common Strategies for Developing Its Inhibitors. ChemBioChem, 24.","DOI":"10.1002\/cbic.202300301"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.csbj.2022.03.009","article-title":"Inhibition of the main protease of SARS-CoV-2 (M(pro)) by repurposing\/designing drug-like substances and utilizing nature\u2019s toolbox of bioactive compounds","volume":"20","author":"Antonopoulou","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1039\/D3MD00493G","article-title":"On the origins of SARS-CoV-2 main protease inhibitors","volume":"15","author":"Janin","year":"2024","journal-title":"RSC Med. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Wilders, H., Biggs, G., Rowe, S.M., Cawood, E.E., Riziotis, I.G., Rendina, A.R., Grant, E.K., Pettinger, J., Fallon, D.J., and Skehel, M. (2024). Expedited SARS-CoV-2 Main Protease Inhibitor Discovery through Modular \u2018Direct-to-Biology\u2019 Screening. Angew Chem. Int. Ed., e202418314.","DOI":"10.1002\/anie.202418314"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"114929","DOI":"10.1016\/j.celrep.2024.114929","article-title":"An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo","volume":"43","author":"Zhou","year":"2024","journal-title":"Cell Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.4155\/fmc-2020-0180","article-title":"Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics","volume":"12","author":"VanPatten","year":"2020","journal-title":"Future Med. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12195-020-00658-5","article-title":"Structure-Based Design of Novel Peptidomimetics Targeting the SARS-CoV-2 Spike Protein","volume":"14","author":"Alagumuthu","year":"2021","journal-title":"Cell. Mol. Bioeng."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"17454","DOI":"10.1021\/acs.jmedchem.4c01404","article-title":"Identification of Potent, Broad-Spectrum Coronavirus Main Protease Inhibitors for Pandemic Preparedness","volume":"67","author":"Barkan","year":"2024","journal-title":"J. Med. Chem"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1021\/acs.jmedchem.9b01828","article-title":"\u03b1-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment","volume":"63","author":"Zhang","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/cmdc.202000924","article-title":"A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors","volume":"16","author":"Yang","year":"2021","journal-title":"ChemMedChem"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1080\/07391102.2020.1771424","article-title":"Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main protease","volume":"39","author":"Choudhury","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1042\/BST0391371","article-title":"Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery","volume":"39","author":"Ramajayam","year":"2011","journal-title":"Biochem. Soc. Trans."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"eabc5332","DOI":"10.1126\/scitranslmed.abc5332","article-title":"3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice","volume":"12","author":"Rathnayake","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1039\/D3OB00381G","article-title":"Synthesis of SARS-CoV-2 M(pro) inhibitors bearing a cinnamic ester warhead with in vitro activity against human coronaviruses","volume":"21","author":"Citarella","year":"2023","journal-title":"Org. Biomol. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","article-title":"Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa","volume":"603","author":"Viana","year":"2022","journal-title":"Nature"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1021\/acs.jpclett.2c00469","article-title":"Omicron BA.2 (B.1.1.529.2): High potential to becoming the next dominating variant","volume":"13","author":"Chen","year":"2022","journal-title":"J. Phys. Chem. Lett."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMc2119641","article-title":"Plasma Neutralization of the SARS-CoV-2 Omicron Variant","volume":"386","author":"Schmidt","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Duan, X., Lacko, L.A., and Chen, S. (2022). Druggable targets and therapeutic development for COVID-19. Front. Chem., 10.","DOI":"10.3389\/fchem.2022.963701"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12250-015-3711-3","article-title":"Recent progress in the discovery of inhibitors targeting coronavirus proteases","volume":"31","author":"Wang","year":"2016","journal-title":"Virol. Sin."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41594-020-0440-6","article-title":"Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur","volume":"27","author":"Jin","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jpha.2020.03.009","article-title":"Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plants","volume":"10","author":"Alqahtani","year":"2020","journal-title":"J. Pharm. Anal."},{"key":"ref_106","first-page":"3213","article-title":"A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2","volume":"39","author":"Islam","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_107","first-page":"4529","article-title":"In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking","volume":"24","author":"Joshi","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1080\/07391102.2020.1768151","article-title":"Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach","volume":"39","author":"Mittal","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1021\/acs.jcim.0c00179","article-title":"Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study","volume":"60","author":"Wang","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1080\/07391102.2020.1766572","article-title":"Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors","volume":"39","author":"Bhardwaj","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Fischer, A., Sellner, M., Neranjan, S., Smie\u0161ko, M., and Lill, M.A. (2020). Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds. Int. J. Mol. Sci., 21.","DOI":"10.26434\/chemrxiv.11923239"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e2000028","DOI":"10.1002\/minf.202000028","article-title":"Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3\u2005Billion Compounds","volume":"39","author":"Ton","year":"2020","journal-title":"Mol. Inform."},{"key":"ref_114","first-page":"3099","article-title":"Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease","volume":"39","author":"Joshi","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"100345","DOI":"10.1016\/j.imu.2020.100345","article-title":"Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study","volume":"19","author":"Peele","year":"2020","journal-title":"Inform. Med. Unlocked"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1080\/07391102.2020.1769733","article-title":"Marine natural compounds as potents inhibitors against the main protease of SARS-CoV-2-a molecular dynamic study","volume":"39","author":"Khan","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1080\/07391102.2020.1776157","article-title":"Identification of potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studies","volume":"39","author":"Gupta","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_118","first-page":"3092","article-title":"Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: An in silico approach","volume":"39","author":"Enmozhi","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1080\/07391102.2020.1758790","article-title":"Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational investigations","volume":"39","author":"Aanouz","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Yang, H., Xie, W., Xue, X., Yang, K., Ma, J., Liang, W., Zhao, Q., Zhou, Z., Pei, D., and Ziebuhr, J. (2005). Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol., 3.","DOI":"10.1371\/journal.pbio.0030428"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1128\/JVI.02685-15","article-title":"Crystal Structure of Feline Infectious Peritonitis Virus Main Protease in Complex with Synergetic Dual Inhibitors","volume":"90","author":"Wang","year":"2016","journal-title":"J. Virol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Wang, F., Chen, C., Tan, W., Yang, K., and Yang, H. (2016). Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design. Sci. Rep., 6.","DOI":"10.1038\/srep22677"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1021\/acs.jmedchem.7b00103","article-title":"Michael Acceptor-Based Peptidomimetic Inhibitor of Main Protease from Porcine Epidemic Diarrhea Virus","volume":"60","author":"Wang","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1126\/science.abf7945","article-title":"X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease","volume":"372","author":"Reinke","year":"2021","journal-title":"Science"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Ma, C., Sacco, M.D., Hurst, B., Townsend, J.A., Hu, Y., Szeto, T., Zhang, X., Tarbet, B., Marty, M.T., and Chen, Y. (2020). Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. bioRxiv.","DOI":"10.1101\/2020.04.20.051581"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Su, H., Yao, S., Zhao, W., Li, M., and Xu, Y. (2020). Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro. bioRxiv, 1\u201329.","DOI":"10.1101\/2020.04.13.038687"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejmech.2017.03.004","article-title":"Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders","volume":"131","author":"Dinda","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_128","unstructured":"FDA (2021, December 22). Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Anastassopoulou, C., Hatziantoniou, S., Boufidou, F., Patrinos, G.P., and Tsakris, A. (2022). The Role of Oral Antivirals for COVID-19 Treatment in Shaping the Pandemic Landscape. J. Pers. Med., 12.","DOI":"10.3390\/jpm12030439"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Chen, W., Shao, Y., Peng, X., Liang, B., Xu, J., and Xing, D. (2022). Review of preclinical data of PF-07304814 and its active metabolite derivatives against SARS-CoV-2 infection. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1035969"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Boras, B., Jones, R.M., Anson, B.J., Arenson, D., Aschenbrenner, L., Bakowski, M.A., Beutler, N., Binder, J., Chen, E., and Eng, H. (2021). Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19. bioRxiv.","DOI":"10.1101\/2020.09.12.293498"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"de Vries, M., Mohamed, A.S., Prescott, R.A., Valero-Jimenez, A.M., Desvignes, L., O\u2019Connor, R., Steppan, C., Devlin, J.C., Ivanova, E., and Herrera, A. (2021). A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL(pro) inhibitor PF-00835231 as a potential new treatment for COVID-19. J. Virol., 95.","DOI":"10.1128\/JVI.01819-20"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Ullrich, S., Ekanayake, K.B., Otting, G., and Nitsche, C. (2022). Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. Bioorganic Med. Chem. Lett., 62.","DOI":"10.1016\/j.bmcl.2022.128629"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41467-022-28354-0","article-title":"The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern","volume":"13","author":"Abdelnabi","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.coviro.2021.04.006","article-title":"Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection","volume":"49","author":"Vandyck","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.heares.2006.08.006","article-title":"Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase","volume":"226","author":"Kil","year":"2007","journal-title":"Hear. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0140-6736(17)31791-9","article-title":"Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"390","author":"Kil","year":"2017","journal-title":"Lancet"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.cbpa.2008.03.009","article-title":"Peptidomimetics, a synthetic tool of drug discovery","volume":"12","author":"Vagner","year":"2008","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/07391102.2020.1819880","article-title":"Computational insight of dexamethasone against potential targets of SARS-CoV-2","volume":"40","author":"Fadaka","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Morgan, P., Arnold, S.J., Hsiao, N.W., and Shu, C.W. (2021). A Closer Look at Dexamethasone and the SARS-CoV-2-Induced Cytokine Storm: In Silico Insights of the First Life-Saving COVID-19 Drug. Antibiotics, 10.","DOI":"10.3390\/antibiotics10121507"},{"key":"ref_142","unstructured":"Eugene, S. (2021, January 20). Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19 (DOXYCOV), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04715295."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Gendrot, M., Andreani, J., Jardot, P., Hutter, S., Delandre, O., Boxberger, M., Mosnier, J., Le Bideau, M., Duflot, I., and Fonta, I. (2020). In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2. Molecules, 25.","DOI":"10.3390\/molecules25215064"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"118080","DOI":"10.1016\/j.lfs.2020.118080","article-title":"Computational insights into tetracyclines as inhibitors against SARS-CoV-2 M(pro) via combinatorial molecular simulation calculations","volume":"257","author":"Bharadwaj","year":"2020","journal-title":"Life Sci."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.str.2020.10.007","article-title":"Malleability of the SARS-CoV-2 3CL M(pro) Active-Site Cavity Facilitates Binding of Clinical Antivirals","volume":"28","author":"Kneller","year":"2020","journal-title":"Structure"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e2021946118","DOI":"10.1073\/pnas.2021946118","article-title":"Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP","volume":"118","author":"Naydenova","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Shannon, A., Selisko, B., Le, N., Huchting, J., Touret, F., Piorkowski, G., Fattorini, V., Ferron, F., Decroly, E., and Meier, C. (2020). Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase. bioRxiv.","DOI":"10.1101\/2020.05.15.098731"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Baker, J.D., Uhrich, R.L., Kraemer, G.C., Love, J.E., and Kraemer, B.C. (2021). A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0245962"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41594-021-00570-0","article-title":"Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin","volume":"28","author":"Yin","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41573-022-00542-z","article-title":"Advances in covalent drug discovery","volume":"21","author":"Boike","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1021\/acsomega.2c03881","article-title":"Novel Investigational Anti-SARS-CoV-2 Agent Ensitrelvir \u201cS-217622\u201d: A Very Promising Potential Universal Broad-Spectrum Antiviral at the Therapeutic Frontline of Coronavirus Species","volume":"8","author":"Eltayb","year":"2023","journal-title":"ACS Omega"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e0069722","DOI":"10.1128\/aac.00697-22","article-title":"A randomized phase 2\/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: Results of the phase 2a part","volume":"66","author":"Mukae","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"105227","DOI":"10.1016\/j.antiviral.2021.105227","article-title":"COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment\u2014Meeting report from an isirv-WHO virtual conference","volume":"197","author":"Hay","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Ullrich, S., and Nitsche, C. (2020). The SARS-CoV-2 main protease as drug target. Bioorg. Med. Chem. Lett., 30.","DOI":"10.1016\/j.bmcl.2020.127377"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"105450","DOI":"10.1016\/j.antiviral.2022.105450","article-title":"In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2","volume":"208","author":"Shang","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"115503","DOI":"10.1016\/j.ejmech.2023.115503","article-title":"Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China","volume":"257","author":"Yang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12519-022-00612-7","article-title":"Treatment of hepatitis C in children and adolescents: How far have we reached?","volume":"19","author":"Venkatesh","year":"2023","journal-title":"World J. Pediatr."},{"key":"ref_160","unstructured":"(2023, July 20). Patsnap. Available online: https:\/\/synapse.zhihuiya.com\/drug-list?query_id=c387e3c8-7f58-46e2-80e9-3d56c80de72d&tab=table."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e01833-01820","DOI":"10.1128\/mBio.01833-20","article-title":"GRL-0920, an indole chloropyridinyl ester, completely blocks SARS-CoV-2 infection","volume":"11","author":"Hattori","year":"2020","journal-title":"mBio"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1017\/ice.2017.76","article-title":"A multicenter randomized trial to determine the effect of an environmental disinfection intervention on the incidence of healthcare-associated Clostridium difficile infection","volume":"38","author":"Ray","year":"2017","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/jmri.21227","article-title":"Chronic hepatitis: Role of diffusion-weighted imaging and diffusion tensor imaging for the diagnosis of liver fibrosis and inflammation","volume":"28","author":"Taouli","year":"2008","journal-title":"J. Magn. Reson. Imaging JMRI"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e153165","DOI":"10.1172\/jci.insight.153165","article-title":"Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties","volume":"7","author":"Bennett","year":"2022","journal-title":"JCI Insight"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40199-021-00401-z","article-title":"Putative role of natural products as Protein Kinase C modulator in different disease conditions","volume":"29","author":"Singh","year":"2021","journal-title":"Daru J. Fac. Pharm."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/2\/351\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:30:01Z","timestamp":1759919401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/2\/351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":165,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["molecules30020351"],"URL":"https:\/\/doi.org\/10.3390\/molecules30020351","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]}}}